Cipher Pharmaceuticals (TSE:CPH) Given a C$12.50 Price Target by Canaccord Genuity Group Analysts

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) has been given a C$12.50 price target by stock analysts at Canaccord Genuity Group in a research report issued on Monday,BayStreet.CA reports. The brokerage presently has a “hold” rating on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 5.04% from the stock’s previous close.

Cipher Pharmaceuticals Stock Performance

CPH traded down C$0.32 during midday trading on Monday, reaching C$11.90. The company’s stock had a trading volume of 47,399 shares, compared to its average volume of 35,718. The company has a current ratio of 2.00, a quick ratio of 2.67 and a debt-to-equity ratio of 41.22. The stock has a market cap of C$213.64 million, a P/E ratio of 13.14 and a beta of 1.20. The company has a fifty day simple moving average of C$12.64 and a 200 day simple moving average of C$14.13. Cipher Pharmaceuticals has a twelve month low of C$8.01 and a twelve month high of C$19.69.

Insider Activity at Cipher Pharmaceuticals

In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin sold 3,500 shares of the company’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of C$13.49, for a total value of C$47,215.00. 42.00% of the stock is currently owned by insiders.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.